Europe
Interim results from COMPACT, a multi-country, real-world study of Erelzi for approved rheumatic diseases presented at 2019 ACR/ARP Annual Meeting
Promore Pharma AB, a Swedish biopharmaceutical developer of therapeutic peptides, announced that its subsidiary Pergamum AB was granted a patent in the US for the pharmaceutical formulation of the product candidate PXL01.
The ISO 13485 audit is an essential qualification for medical device manufacturers, showing HRA Pharma’s commitment to the highest quality standard.
Leading immuno-oncology company adopts Genedata Biologics® to support the discovery and development of TCRs for adoptive cell therapies and bispecific TCR molecules
Scientists save time and reduce costs by only ordering compounds with suitable solubility; aids screening library selection and sourcing
Outstanding dedication to quality, science and customer service helped RSSL secure Best Contract Research Organisation at this year’s Oxford Bioscience Network (OBN) Awards.
Second Orphan Drug Designation granted by the European Commission for leriglitazone, in addition to X-linked adrenoleukodystrophy (X-ALD)
Over 15,000 patients worldwide already treated with Letermovir to prevent Cytomegalovirus (CMV) infection and disease in allogeneic stem cell transplantation
Polarean Imaging plc, the medical-imaging technology company, with a proprietary drug-device combination product for the magnetic resonance imaging market, announces that further to the announcement of 15 February 2019, the Company has delivered and installed its latest research unit order for a 9820 Xenon Polariser system from the University of British Columbia https://www.ubc.ca/.
Lonza announced that Marc Funk, CEO, will leave the Company for personal reasons. The Board of Directors also announced that Albert Baehny, Chairman, will take on the additional responsibility of Chief Executive Officer on an ad interim basis until a permanent successor is found.
PRESS RELEASES